title: Glutest Neo Super--a new handheld blood glucose meter-corrects for the effects of the hematocrit values in both hematocrit-adjusted samples and samples obtained from anemic patients.
abstract: BACKGROUND
  Handheld blood glucose (BG) meters are convenient tools that are widely used to measure the BG levels. However, the hematocrit (Hct) value has been identified as a confounding factor for accurate BG measurement. Some BG meters are equipped with an Hct-correcting feature, whose effectiveness has been tested previously. Nevertheless, the measurements yielded by many BG meters are confounded by the Hct values. Recently, a new BG meter equipped with an Hct-correcting feature has been developed; however, its effectiveness has not yet been confirmed.
  
  
  METHODS
  Venous blood samples were collected from two healthy volunteers, and the Hct values in the samples were adjusted to approximately 0%, 10%, 20%, 30%, 40%, 50%, and 60%. Further, venous blood samples were collected from 10 anemic patients (Hct <40%). The whole BG (WBG) levels in the samples were measured using two devices-the new BG meter (Glutest Neo Super [Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya, Japan]) and a standard BG meter (OneTouch Ultra [Life Scan Inc., Milpitas, CA]). For reference, plasma glucose (PG) levels were measured using a machine at our hospital laboratory (GA08 [A&T Co., Kanagawa, Japan]). The bias in the measurements was calculated as follows: bias = ([WBG - PG]/PG) x 100. Further, the correlation between the Hct values and the bias was assessed by performing linear regression analysis.
  
  
  RESULTS
  In both the Hct-adjusted samples and the samples obtained from anemic patients, the WBG levels measured using Glutest Neo Super were minimally affected by the Hct values, while those measured using OneTouch Ultra were affected by the Hct values to a statistically significant extent.
  
  
  CONCLUSIONS
  The Hct-correcting feature of the new BG meter Glutest Neo Super was effective. The use of this new device for BG measurements may lead to more appropriate treatment selection.
authors.affiliation: Department of Internal Medicine, Toranomon Hospital, Tokyo, Japan. clinic@nifty.com
authors.forename: Fumiatsu
authors.initials: F
authors.lastname: Yakushiji
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Joukyu
authors.forename: Mutsuko
authors.initials: M
authors.lastname: Yasuda
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Terayama
authors.forename: Kaoru
authors.initials: K
authors.lastname: Nagasawa
authors.forename: Akira
authors.initials: A
authors.lastname: Ohwada
authors.forename: Ken
authors.initials: K
authors.lastname: Taniguchi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Fujiki
authors.forename: Masako
authors.initials: M
authors.lastname: Shimojo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kinoshita
mesh_terms: D000740:Anemia / Q000097:blood* / Q000175:diagnosis; D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000295:instrumentation*; D004867:Equipment Design; D006400:Hematocrit; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D012016:Reference Values
chemical_list: D001786:Blood Glucose; D006493:Heparin